| Name | Title | Contact Details |
|---|---|---|
Vinay Gidwaney |
Head of Technology | Profile |
Delmont Labs is a Swarthmore, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
S Epilepsy is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Based in Denver, Cordant Health Solutions™ provides innovative tools for monitoring and managing behavioral health, chronic pain and criminal justice cases. Our unique programs include pharmacy, clinical laboratory and analytic tools that provide actionable information to protect prescribers, improve outcomes and contain costs. As a leader in rigorous quality and compliance standards, Cordant is committed to developing groundbreaking solutions for payers, clinicians and organizations involved in the substance use disorder, criminal justice and pain management markets. Cordant offers unique risk assessment, monitoring and management tools through its integrated network of laboratories and high-touch pharmacies specializing in the management and dispensing of controlled substances and behavioral health medications. Cordant`s testing protocols and digital case-management tools help clients become more efficient and effective in assessing and managing risk, monitoring patient adherence and improving patient outcomes.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Hortense and Louis Rubin Dialysis Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Troy, NY. To find more information about Hortense and Louis Rubin Dialysis Center, please visit www.rubindialysis.org